Therefore Ptpn2 has recently been identified as a novel cancer immunotherapy target in a CRISPR screening in vivo, where deletion of this gene increased the efficacy of immune checkpoint blockade therapy in melanoma (45). Here, PTPN2 is linked to melanoma.